Psychosis induced by the interaction of memantine and amantadine: Lending evidence to the glutamatergic theory of schizophrenia

Clinical Schizophrenia and Related Psychoses

Volumn 1, Issue 3, 2007, Pages 273-276

  Spiegel, David R ^a   Leader, Michael R ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Brain Injury; Glutamate; Psychosis

Indexed keywords

AMANTADINE; DONEPEZIL; GLUTAMIC ACID; MEMANTINE; OLANZAPINE; VALPROIC ACID;

ADULT; AKINESIA; ARTICLE; ATTENTION; AUDITORY HALLUCINATION; BEDTIME DOSAGE; CASE REPORT; CATATONIA; CLINICAL FEATURE; COGNITIVE DEFECT; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG INTERACTION; DRUG WITHDRAWAL; FRONTAL LOBE SYNDROME; GRANDIOSE DELUSION; HUMAN; MALE; NEUROLOGIC EXAMINATION; ORIENTATION; POSITIVE SYNDROME; PSYCHOSIS; RESTLESSNESS; SCHIZOPHRENIA; SHORT TERM MEMORY; SIDE EFFECT; SPEECH DISCRIMINATION; STEREOTYPY; TRAFFIC ACCIDENT; VISUAL HALLUCINATION;

EID: 67649718286     PISSN: 19351232     EISSN: None     Source Type: Journal    
DOI: 10.3371/CSRP.1.3.7     Document Type: Article

References (19)

1. Higgins ES, George MS. Te neuroscience of clinical psychiatry: the pathophysiology of behavior and mental illness. 1st ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2007.
2. Kaufman DM. Clinical neurology for psychiatrists. 6th ed. Philadelphia (PA): Saunders; 2007.
3. Kraus MF, Maki PM. Efect of amantadine hydrochloride on symptoms of frontal lobe dysfunction in brain injury: case studies and review. J Neuropsychiatry Clin Neurosci 1997;9(2):222-230.
4. Spiegel D, et al. Treatment of akinetic mutism with intramuscular olanzapine: a case series. J Neuropsychiatry Clin Neurosci. In press 2007.
5. Sugden SG, Kile SJ, Farrimond DD, Hilty DM, Bourgeois JA. Pharmacological intervention for cognitive defcits and aggression in frontal lobe injury. NeuroRehabilitation 2006;21(1):3-7.
6. Andreasen NC. Methods for assessing positive and negative symptoms. In: Andreasen NC, editor. Schizophrenia: positive and negative symptoms and syndromes. (Modern Problems in Pharmacopsychiatry series, vol. 24). Basel (Switzerland): S. Karger AG; 1990.
7. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, et al. NMDA receptor function and human cognition: the efects of ketamine in healthy volunteers. Neuropsychopharmacology 1996;14(5):301-307.
8. Sharp FR, Tomitaka M, Bernaudin M, Tomitaka S. Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia? Trends Neurosci 2001;24(6):330-334.
9. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist-a review of preclinical data. Neuropharmacology 1999;38(6):735-767.
10. Lewis DA, Glantz LA, Pierri JN, Sweet RA. Altered cortical glutamate neurotransmission in schizophrenia: evidence from morphological studies of pyramidal neurons. Ann N Y Acad Sci 2003;1003:102-112.
11. Te Pharmacogenetics and Pharmacogenomics Knowledge Base (PharmGKB). Amantadine. [accessed 2006 Aug 6]. Available from: http://www.pharmgkb.org/do/ serve?objId= PA448360&objCls=Drug
12. Chen HS, Lipton SA. Pharmacological implications of two distinct mechanisms of interaction of memantine with N-methyl-D-aspartate-gated channels. J Pharmacol Exp Ter 2005;314(3):961-971.
13. Huey ED, Dustin IH, Overman G P, Mirza N, Sunderland T. Development of subtle psychotic symptoms with memantine: a case report. J Clin Psychiatry 2005;66(5):658-659.
14. Blanpied TA, Clarke RJ, Johnson J W. Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J Neurosci 2005;25(13):3312-3322.
15. Parsons CG, Quack G, Bresink I, Baran L, Przegalinski E, Kostowski W, et al. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 1995;34(10):1239-1258.
16. Carroll BT, Tomas C, Jayanti K. Amantadine and me-mantine in catatonic schizophrenia. Ann Clin Psychiatry 2006;18(2):133-134.
17. Cassidy EM, O'Brien M, Osman MF, Finucane J, O'Keane V. Lethal catatonia responding to high-dose olanzapine therapy. J Psychopharmacol 2001;15(4):302-304.
18. Gobbi G, Janiri L. Sodium- and magnesium-valproate in vivo modulate glutamatergic and GABAergic synapses in the medial prefrontal cortex. Psychopharmacology (Berl) 2006;185(2):255-262.
19. Fusar-Poli P, Perez J, Broome M, Borgwardt S, Placentino A, Caverzasi E, et al. Neurofunctional correlates of vulnerability to psychosis: a systematic review and meta-analysis. Neurosci Biobehav Rev 2007;31(4):465-484.